MDMA (Ecstasy)

References

• Merck E: Verfahren zur darstellung von alkyloxyaryl-dialy-loxyarylund alkylenedioxy-arylaminopropanen bzw. deren am stickstoffinonalkylieten derivaten. German Patent #273,350. 1914
   Google Scholar
• Hardman HF, Haavik CO, Seevers MH: Relationship of the struc-ture of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol Appl Pharmacol 1973; 25:299–309.
   PubMed Web of Science ®Google Scholar
• Shulgin AT, Nichols DE: Characterization of three new psycho-mimetics. In Stillman R, Willette R (eds.): The Psychopharmacol-ogy of Hallucinogens. New York: Pergamon Press. 1978: 74–83.
   Google Scholar
• Lawn JC: Schedules of controlled substances: Scheduling of 3,4-methylenedioxymethamphetamine (MDMA) into Schedule I of the Controlled Substances Act. Fed Register 1986; 51:36552–36560
   Google Scholar
• Peroutka SJ: Incidence of recreational use of 3,4-methylene-dioxymethamphetamine (MDMA, "Ecstasy") on an undergradu-ate campus. N Engl J Med 1987; 317:1542–1543
   PubMed Web of Science ®Google Scholar
• Pope HG Jr, Ionescu-Pioggia M, Pope KW: Drug use and life style among college undergraduates: A 30-year longitudinal study. Am J Psychiatry 2001; 158:1519–1521
   Google Scholar
• Peroutka SJ, Newman H, Harris H: Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neurop-sychopharmacol 1988; 1:273–277
   PubMed Web of Science ®Google Scholar
• Strote J, Lee JE, Wechsler H: Increasing MDMA use among col-lege students: Results of a national survey. J Adolesc Health 2002; 30:64–72
   PubMed Web of Science ®Google Scholar
• Cuomo MJ, Dyment PG, Gammino VM: Increasing use of "ecstasy" (MDMA) and other hallucinogens on a college campus. J Am College Health 1994; 42:272–274
   Google Scholar
• Randell T: Rave scene, ecstasy use, leap Atlantic. J Am Med Assoc 1992; 268:1506
   Google Scholar
• Johnston LD, O'Malley PM, Bachman JG: National survey results on drug use from the Monitoring the Future Study, 1975–1998. Volume I. Secondary school students. NIH Publication No. 99–4660. Washington, DC; U.S. Department of Health and Human Services. 1999
   Google Scholar
• Topp L, Hando J, Dillon P, et al.: Ecstasy use in Australia: Pat-terns of use and associated harm. Drug Alcohol Depend 1999; 55:105–115
   Google Scholar
• Cregg MT, Traqcey JA: Ecstasy abuse in Ireland. Irish Med J 1993; 86:118–120
   PubMedGoogle Scholar
• Christophersen AS: Amphetamine designer drugs-An overview and epidemiology. Toxicol Lett 2000; 112–113:127-131
   Google Scholar
• Landry MJ: MDMA: A review of epidemiolgic data. J Psychoac-tive Drugs 2002; 34:163–169
   PubMed Web of Science ®Google Scholar
• Downing J: The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 1986; 18:335–340
   PubMed Web of Science ®Google Scholar
• Siegel RK: MDMA: Nonmedical use and intoxication. J Psycho-active Drugs 1986; 18:349–354
   PubMed Web of Science ®Google Scholar
• Liester MB, Grob CS, Bravo GL, et al.: Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nervous Mental Dis 1992; 180: 345–352
   Google Scholar
• Brown ER, Jarvie DR, Simpson D: Use of drugs at "raves." Scott Med J1995; 40:168–171
   PubMed Web of Science ®Google Scholar
• Forsyth AJ: Places and patterns of drug use in the Scottish dance scene. Addiction 1996; 91:511–521
   PubMed Web of Science ®Google Scholar
• Gervin M, Hughes R, Bamford L, et al.: Heroin smoking by "chasing the dragon" in young opiate users in Ireland: Stability and associations with use to "come down" of "Ecstasy." J Sub Abuse Treat 2001; 20: 297–300
   Google Scholar
• Gerhard H: Party-drugs: Sociocultural and individual background and risks. Int J Clin Pharmacol Therap 2001; 39:362–366
   Google Scholar
• Yacoubian GS Jr, Boyle C, Harding CA, et al.: It's a rave new world: Estimating the prevalence and perceived harm of ecstasy and other drug use among club rave attendees. J Drug Educ 2003; 33: 187–196 11.
   Google Scholar
• Dundes L: DanceSafe and ecstasy: Protection or promotion?J Health Soc Policy 2003; 17:19–37
   Google Scholar
• Shulgin AT, Nichols DE: Characterization of three new psychomimetics. In Stillman R, Willette R (Eds.): The psychopharmacology of hallucinogens. New York: Pergamon Press, 1978: 74–83
   Google Scholar
• Greer G, Tolbert P: Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986; 18:319–327
   Google Scholar
• Greer GR, Tolbert P: A method of conducting therapeutic sessions with MDMA. J Psychoactive Drugs 1998; 30:371–379
   Google Scholar
• Reneman L, Majoie CB, Flick H, et al.: Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethamphetamine (Ecstasy) users: Preliminary results. Am J Neuroradiol 2002; 23: 231–237
   Google Scholar
• McCann UD, Szabo Z, Scheffel U, et al.: Positron emission tomographic evidence of toxic effect of MDMA (–Ecstasy–) on brain serotonin neurons in human beings. Lancet 1998; 352:1433–1437
   Google Scholar
• Semple DM, Ebmeier KP, Glabus MF, et al.: Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (–ecstasy–) users. Br J Psychiatry 1999; 175:63–69
   Google Scholar
• Doblin R: A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): Partnering with the FDA. J Psychoactive Drugs 2002; 34:185–194
   Google Scholar
• Ho E, Karimi-Tabesh L, Koren G: Characteristics of pregnant women who use ecstasy (3,4-methylenedioxymethamphetamine). Neurotoxicol Teratol 2001; 23:561–567
   Google Scholar
• Anderson GM, Braun G, Braun U, et al.: Absolute configuration and psychomimetic phenylalkylamines. NIDA Research Monograph
   Google Scholar
• Rockville, MD, 1978
   Google Scholar
• Helmlin H-J, Bracher K, Bourquin D, et al.: Analysis of 3,4- methylenedioxyamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J Analytical Toxicol 1996; 20: 432–440
   Google Scholar
• Fallon JK, Kicman AT, Henry JA, et al.: Stereospecific analysis and enantiomeric disposition of 3,4-methylenedioxymethamphetamine (Ecstasy) in humans. Clin Chem 1999; 45: 1058–1069
   Google Scholar
• Maurer HH, Bickeboeller-Friedrich J, Kraemer T, et al.: Toxcicokinetics and analytical toxicology of amphetaminederived designer drugs (–Ecstasy–). Toxicol Lett 2000; 112– 113:133–142
   Google Scholar
• Segura M, Ortuno J, Farre M, et al.: 3,4-Dihydroxymethamphetamine (HHMA): A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 2001; 14: 1203–1208
   Google Scholar
• de la Torre R, Farre M, Ortuno J, et al.: Non-linear pharmacokinetics of MDMA (–ecstasy–) in humans. Br J Clin Pharmacol 2000; 49:104–109
   Google Scholar
• Verebey K, Alrazi J, Jaffe JU: The complications of –ecstasy– (MDMA). J Am Med Assoc 1988; 259:1649–1650
   Google Scholar
• Mas M, Farre M, de la Torre R, et al.: Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Therap 1999; 290: 136–145
   Google Scholar
• Pacifici R, Farre M, Pichini S, et al.: Sweat testing of MDMA with the Drugwipe analytical device: A controlled study with two volunteers. J Analyt Toxicol 2001; 25:144–146
   Google Scholar
• Johnson MP, Hoffman AH, Nichols DE: Effects of the enantiomers of MDA, MDMA and related analogues on [3H]-serotonin and [3H]-dopamine release from superfused rat brain slices. Eur J Pharmacol 1986; 132:269–276
   Google Scholar
• McKenna DJ, Peroutka SJ: Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, –ecstasy–). J Neurochem 1990; 54:14–22
   Google Scholar
• Yamamoto BK, Spanos LJ: The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 1988; 148:195–203
   Google Scholar
• Hiramatsu M, Cho AK: Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats. Neuropharmacol 1990; 29:269–275
   Google Scholar
• Nash JF, Meltzer HY, Gudelsky GA: Effect of 3,4-methylenedioxymethamphetamine accumulation in the striatum and nucleus accumbens. J Neurochem 1990; 54:1062–1067
   Google Scholar
• Steele TD, Nichols DE, Yim GKW: Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]- monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 1987; 36:2297–2303
   Google Scholar
• Lyon RA, Glennon RA, Titeler M: 3,4-methylenedioxymethamphetamine (MDMA): Stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacol 1986; 88:525–526
   Google Scholar
• Bettaglia G, Brooks BP, Kulsakdinum C, et al.: Pharmacologic profile of MDMA (3,4-methylenedioxymethaphetamine) at various brain recognition sites. Eur J Pharmacol 1988; 149: 159–163
   Google Scholar
• Acquas E, Marrocu P, Pisanu A, et al.: Intravenous administration of ecstasy (3,4-methylenedioxymethamphetamine) ebhances cortical and striatal acetylcholine release in vivo. Eur J Pharmacol 2001; 418: 207–211
   Google Scholar
• Stone DM, Stahl DC, Hanson GR, et al.: The effects of 3,4- methylenedioxymethamphetamine (MDMA) and 3,4-methlenedioxyamphetamine (MDA) on monaminergic systems in the rat brain. Eur J Pharmacol 1986; 128: 41–48
   Google Scholar
• Schmidt CJ, Wu L, Lovenberg W: Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analog. Eur J Pharmacol 1986; 124:175–178
   Google Scholar
• Schmidt CJ: Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 1987; 240:1–7
   Google Scholar
• Commins DL, Vosmer G, Virus RM, et al.: Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987; 241:338–345
   Google Scholar
• O–Hearn EG, Battaglia G, DeSouza EB, et al.: Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of sertotonergic axon terminals in forebrain: Immunocytochemical evidence for neurotoxicity. J Neurosci 1988; 8:2788–2803
   Google Scholar
• Slikker W, Ali SF, Scallet C, et al.: Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 1988; 94:448–457
   Google Scholar
• Slikker W Jr, Holson RR, Ali SF, et al.: Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicol 1989; 10:529–549
   Google Scholar
• Ricaurte GA, DeLanney LE, Irwin I, et al.: Toxic effects of MDMA on central serotonergic neurons in the primate: Importance of route and frequency of drug administration. Brain Res 1988; 446:165–168
   Google Scholar
• Ricaurte GA, Katz JL, Martello MB: Lasting effects of (+-)- 3,4-methylenedioxymethamphetamine (MDMA) on central
   Google Scholar
• Inset TR, Battaglia G, Johannessen IN, et al.: 3,4-methylene-dioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther 1989; 249: 713–720
   Google Scholar
• Wilson MA, Ricaurte GA, Molliver ME: Distinct morphological classes of serotonergic axons in primates exhibit differential vul-nerability to the psychotropic drug 3,4-methylenedioxymetham-phetamine. Neurosci 1989; 28:121–137
   PubMed Web of Science ®Google Scholar
• Fischer CA, Hatzidimitriou G, Katz JL, et al.: Reorganization of ascending serotonin axon projections in animals previously exposed to the recreational drug 3,4-methylenedioxymethamphet-amine J Neurosci 1995; 15: 5476–5485
   Google Scholar
• Hatzidimitriou G, McCann UD, Ricaurte GA: Abnormal seroto-nin innervation in the forebrain of monkeys exposed to MDMA seven years previously: Factors influencing abnormal recovery. J Neurosci 1999; 19:5096–5107
   PubMed Web of Science ®Google Scholar
• McCann UD, Ridenour A, Shaham Y, et al.: Brain serotonergic neurotoxicity after MDMA ("ecstasy"): A controlled study in humans. Neuropsychopharmacol 1994; 10: 129–138
   Google Scholar
• Reneman L, Majoie CB, Schmand B, et al.: Prefrontal N-acetylaspartate is strongly associated with memory performance in (abstinent) ecstasy users: preliminary report. Biol Psychiatry 2001; 50:550–554
   Google Scholar
• Reneman L, Majoie CB, Flick H, et al.: Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethamphet-amine (ecstasy) users: preliminary results. Am J Neuroradiol 2002; 23: 231–237
   Google Scholar
• Cowan RL, Lyoo IK, Sung SM, et al.: Reduced cortical gray matter density in human MDMA (Ecstasy) users: a voxel-based morphometry study. Drug Alcohol Depend 2003; 72:225–235
   Google Scholar
• McCann UD, Szabo Z, Scheffel U, et al.: Positron emission tomo-graphic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 1998; 352: 1433–1437
   Google Scholar
• Semple DM, Ebmeier KP, Glabus MF, et al.: Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry 1999; 175:63–69
   Google Scholar
• Reneman L, Lavalaye J, Schmand B, et al.: Cortical serotonin trans-porter density and berbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): Preliminary findings. Arch Gen Psychiatry 2001; 58: 907–908
   Google Scholar
• Reneman L, Booij J, de Bruin K, et al.: Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 2001; 358:1864–1869
   Google Scholar
• Ricaurte GA, Yuan J, Hatzidimitriou G, et al.: Severe dopaminer-gic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy"). Science 2002; 297: 2260–2263
   PubMed Web of Science ®Google Scholar
• Ricaurte GA, Yuan J, Hatzidimitriou G, et al.: Retraction of Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy"). Science 2002; 297:2260-2263. Science 2003; 301: 1479
   Google Scholar
• Vollenweider FX, Gamma A, Liechti M, et al.: Psychological and cardiovascular effects and short-term sequelae of MDMA ("Ecstasy") in MDMA-naïve healthy volunteers. Neuropsycho-pharmacol 1998; 19: 241–251
   PubMed Web of Science ®Google Scholar
• Grab CS, Poland RE, Chang L, et al.: Psychobiologic effects of 3,4-methylendioxymethamphetamine in humans: Methodological considerations and preliminary observations. Behav Brain Res 1996; 73: 103–107
   Google Scholar
• Mas M, Farm M, de la Torre R, et al.: Cardiovacular and neuroendocrine effects and pharmacokinetics of 3,4-methylene-dioxymethamphetamine in humans. J Pharmacol Exp Ther 1999; 290: 136–145
   Google Scholar
• Tamer ME, Johanson CE: The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alc Depend 2001; 65:97–101
   Google Scholar
• Zemishlany Z, Aizenberg D, Weizman A: Subjective effects of MDMA (`Ecstasy') on human sexual function. Eur Psychiatry: J Assoc Eur Psychiatrists 2001; 16:127–130
   PubMed Web of Science ®Google Scholar
• Vaiva G, Boss V, Bailly D, et al.: An "accidental" acute psychosis with ecstasy use. J Psychoactive Drugs 2001; 33: 95–98
   PubMed Web of Science ®Google Scholar
• Creighton FJ, Black DL, Hyde CE: 'Ecstasy' psychosis and flash-backs. Br J Psychiatry 1991; 159:713–715
   PubMed Web of Science ®Google Scholar
• Cox DE: "Rave" to the grave. Forensic Sci Int 1993; 60:5–6
   Google Scholar
• Dowling GP, McDonough ET, Bost RD: 'Eve' and 'Ecstasy.' A report of five deaths associated with the use of MDEA and MDMA. JAm Med Assoc 1987; 257:1615–1617
   Google Scholar
• Cadier MA, Clarke JA: Ecstasy and Whizz at a rave resulting in a major burn plus complications. Burns 1993; 19:239–240
   Google Scholar
• Hooft PJ, Van der Voorde HP: Reckless behavior related to the use of 3,4-methylenedioxymethamphetamine (ecstasy): Apropos of fatal accident during car surfing. Int J Legal Med 1994; 106:328–329
   Google Scholar
• Bond AJ, Verheyden SL, Wingrove J, et al.: Angry cognitive bias, trait aggression and impulsivity in substance users. Psychophar-macol (Berl) 2004; 17:331–339
   Google Scholar
• Curran HV, Verheyden SL: Altered response to tryptophan sup-plementation after long-term abstention from MDMA (ecstasy) is highly correlated with human memory function. Psychopharma-col (Berl) 2003; 169:91–103
   PubMed Web of Science ®Google Scholar
• Brookhuis KA, De Waard D, Samyn N: Effects of MDMA (ecstasy), and multiple drugs use on (simulated) driving perfor-mance and traffic safety. Psychopharmacol (Berl) 2004; in press
   Google Scholar
• Solowij N, Hall W, Lee N: Recreational MDMA use in Sydney: A profile of 'Ecstasy' users and their experiences with the drug. Br J Addiction 1992; 87:1161–1172
   PubMedGoogle Scholar
• Logan BK, Couper FJ: 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and driving impairment. J Forensic Sci 2001; 46:1426–1433
   PubMed Web of Science ®Google Scholar
• Cifasi J, Long C: Traffic fatality related to the use of methylene-dioxymethamphetamine. J Forensic Sci 1996; 41:1082–1084
   Google Scholar
• Machines N, Handley SL, Harding GF: Former chronic methyl-enedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J Psychopharmacol 2001; 15:181–186
   Google Scholar
• Parrott AC, Milani RM, Parmar R, et al.: Recreational ecstasy/ MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacol 2001; 159:77
   Google Scholar
• Verkes RJ, Gijsman HJ, Pieters RC, et al.: Cognitive performance and serotonergic function in users of ecstasy. Psychopharamacol 2001; 153:186–202
   Google Scholar
• Krystal JH, Price LH: Chronic 3,4-methylenedimethoxymetham-phetamine (MDMA) use: Effects on mood and neuropsychologi-cal function? Am J Drug Alcohol Abuse 1992; 18:331–341
   PubMed Web of Science ®Google Scholar
• Allen RP, McCann UD, Ricourte GA: Persistent effects of +/-3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") on human sleep. Sleep 1993; 16:560–564
   PubMed Web of Science ®Google Scholar
• McGuire P: Long term psychiatric and cognitive effects of MDMA use. Tox Lett 2000; 112–113:153-156
   Google Scholar
• Reneman L, Booij J, Schmand B, et al.: Memory disturbances in "Ecstasy" users are correlated with altered brain serotonin neu-rotransmission. Psychopharm 2000; 148: 322–324
   Google Scholar
• Parrott AC, Lasky J: Ecstasy (MDMA) effects upon mood and cognition: Before, during and after a Saturday night dance. Psychopharmacol 1998; 139:261–268
   PubMed Web of Science ®Google Scholar
• McCann UD, Mertl M, Eligulashvili V. et al.: Cognitive perfor-mance in (+/-) 3,4-methlenedixoymethamphetamine (MDMA, "ecstasy") users: A controlled study. Psychopharmacol 1999; 143:417–425
   Google Scholar
• Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, et al.: Impaired cognitive performance in drug free users of recre-ational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 2000; 68:719–725
   Google Scholar
• Bhattachary S, Powell JH: Recreational use of 3,4-methylene-dioxymethamphetamine (MDMA) or 'ecstasy': Evidence for cognitive impairment. Psychol Med 2001; 31:647–658
   PubMed Web of Science ®Google Scholar
• Croft RJ, Mackay AJ, Mills AT, et al.: The relative contributions of ecstasy and cannabis to cognitive impairment. Psychophar-macol 2001; 153:373–379
   Google Scholar
• Zakzanis KK, Young DA: Memory impairment in abstinent MDMA ("Ecstasy") users: A longitudinal investigation. Neurol 2001; 56:966–969
   PubMed Web of Science ®Google Scholar
• Gouzoulis-Mayfrank E, Thimm B, Rezk M, et al.: Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:819–827
   Google Scholar
• Jacobsen LK, Menet WE, Pugh KR, et al.: Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: Possible relationship to neurotoxic effects. Psychophar-macol (Berl) 2004; 173: 383–390
   Google Scholar
• Verbaten MN: Specific memory deficits in ecstasy users? The results of a meta-analysis. Hum Psychopharmacol 2003; 18:281–290
   PubMedGoogle Scholar
• Oliveri M, Calvo G: Increased visual cortical excitability in ecstasy users: a transcranial magnetic stimulation study. J Neurol Neurosurg Psychiatry 2003; 74:1136–1138
   Web of Science ®Google Scholar
• Wareing M, Murphy PN, Fisk JE: Visuospatial memory impair-ments in users of MDMA ("ecstasy"). Psychopharmacol (Berl) 2004; 173:391–397
   PubMedGoogle Scholar
• Reneman L, Endert E, de Bruin K, et al.: The acute and chronic effects of MDMA ("ecstasy") on cortical 5-HT2, receptors in rat and human brain. Neuropsychopharmacol 2002; 26: 387–396
   Google Scholar
• Harries DP, DeSilva R: 'Ecstasy' and intracerebral haemor-rhage. Scott Med 1992; 37:476
   Google Scholar
• Gledhill JA, Moore DF, Bell D, et al.: Subarachnoid hemorrhage associated with MDMA abuse. J Neurol Neurosurg Psychiatry 1993; 56:1036–1037
   Google Scholar
• Hughes JC, McCube M, Evans RI: Intracranial haemorrhage associated with ingestion of "Ecstasy." Arch Emerg Med 1993; 10:372–374
   PubMedGoogle Scholar
• Manchanda S, Connolly MJ: Cerebral infarction in association with ecstasy abuse. Postgrad Med J1993; 69:874–875
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Grant R: Cerebral venous thrombosis induced by 'ecstasy.' J Neurol Neurosurg Psychiatry 1993; 56:1035–1039
   Google Scholar
• Bertram M, Egelhoff T, Schwarz S, et al.: Toxic leukoencepha-lopathy following "ecstasy" ingestion. J Neurol 1999; 146: 617–618
   Google Scholar
• Qasim A, Townend J, Davies MK: Ecstasy induced acute myo-cardial infarction. Heart (Br Cardiac Soc) 2001; 85:E10
   PubMed Web of Science ®Google Scholar
• Henry JA, Jeffreys KJ, Dowling S: Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 1992; 340:384–387
   PubMed Web of Science ®Google Scholar
• Mazur S, Hitchcock T: Spontaneous pneumomediastinum, pneu-mothorax and ecstasy abuse. Emergency Med (Fremantle, West-ern Australia) 2001; 13:121–123
   Google Scholar
• Shearman JD, Satsangi J, Chapman RWG, et al.: Misuse of Ecstasy. Br Med J1992; 305:309
   Google Scholar
• Ijzermans JNM, Tilanus HW, DeMan RA, et al.: Ecstasy and liver transplantation. Ann Med Interne 1993; 144:568
   Google Scholar
• Khakoo SI, Coles CJ, Armstrong JS, et al.: Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymethamphet-amine ("Ecstasy") usage. J Clin Gastroenterology 1995; 20: 244–247
   PubMed Web of Science ®Google Scholar
• Ellis AJ, Wendon JA, Portmann B, et al.: Acute liver damage and ecstasy ingestion. Gut 1996; 38:454–458
   Google Scholar
• Andreu V. Mas A, Bruguera M, et al.: Ecstasy: A common cause of severe acute hepatotoxicity. J Hepatol 1998; 29:394–397
   Google Scholar
• DeCarlis L, DeGasperi A, Slim AO, et al.: Liver transplantation of ecstasy-induced fulminant hepatic failure. Trans Proc 2001; 33:2743–2744
   Google Scholar
• Lawler LP, Abraham S, Fishman EK: 3,4-methylene-dioxymethamphetamine (ecstasy)-induced hepatotoxicity: multidetector CT and pathology findings. J Computer Assis Tomography 2001; 25:649–652
   PubMedGoogle Scholar
• Marsh JC, Abboudi ZH, Gibson FM, et al.: Aplastic anemia fol-lowing exposure to 3,4-methylenedioxymethamphetamine ('Ecstasy'). Br J Haematol 1994; 88: 281–285
   Google Scholar
• Clark AD, Butt N: Ecstasy-induced very severe aplastic anaemia complicated by invasive pulmonary mucormycosis treated with allogeneic peripheral blood progenitor cell transplant. Clin Lab Haematol 1997; 19:279–281
   PubMedGoogle Scholar
• Spruit IP: Monitoring synthetic drug markets, trends, and public health. Substance Use Misuse 2001; 36:23–47
   PubMed Web of Science ®Google Scholar
• Garcia-Repetto R, Moreno E, Soriano T, et al.: Tissue concentra-tions of MDMA and its metabolite MDA in three fatal cases of overdose. Forensic Sci Int 2003; 135:110–114
   Google Scholar
• Schifano F, Oyefesco A, Webb L, et al.: Reviews of deaths related to taking ecstasy, England and Wales, 1997–2000. Brit Med J2003; 326: 80–81
   Google Scholar
• Maxwell DL, Polkey MI, Henry JA: Hyponatremia and catatonia stupor after taking 'ecstasy.' Br Med J 1993; 27:1399
   Google Scholar
• Kessel B: Hyponatremia after ingestion of "ecstasy." Brit Med J 1994; 308: 414
   PubMed Web of Science ®Google Scholar
• Matthai SM, Davidson DC, Sills JA, et al.: Cerebral oedema after ingestion of MDMA ("ecstasy") and unrestricted intake of water. Br Med J1996; 312: 1359
   Google Scholar
• Hall AP: Hyponatremia, water intoxication and 'ecstasy.' Inten-sive Care Med 1997; 23:1289
   PubMed Web of Science ®Google Scholar
• Ajaelo I, Koenig K, Snoey E: Severe hyponatremia and inappro-priate antidiuretic hormone secretion following ecstasy use. Acad Emerg Med 1998; 5:839–840
   PubMed Web of Science ®Google Scholar
• Magee C, Staunton H, Tormey W, et al.: Hyponatremia, seizures and stupor associated with ecstasy ingestion in a female. Jr Med J1998; 91:178
   Google Scholar
• Holmes SB, Banerjee AK, Alexander WD: Hyponatremia and seizures after ecstasy use. Postgrad Med J1999; 75:32–33
   PubMed Web of Science ®Google Scholar
• O'Connor A, Cluroe A, Couch R, et al.: Death from hyponatremia-induced cerebral oedema associated with MDMA ("Ecstasy") use. NZ Med J1999; 112:255–256
   PubMed Web of Science ®Google Scholar
• Budisavljevic MN, Stewart L, Sahn SA, et al.: Hyponatremia asso-ciated with 3,4-methylenedioxymethylarnphetamine ("Ecstasy") abuse. Am J Med Sci 2003; 326: 89–93
   PubMed Web of Science ®Google Scholar
• Sternbach H: The serotonin syndrome. Am J Psychiatry 1991; 148:705–713
   PubMed Web of Science ®Google Scholar
• Demirkiran M, Jankovic J, Dean JM: Ecstasy intoxication: An overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropsychopharmacol 1996; 19:157–164
   PubMed Web of Science ®Google Scholar
• Mueller PD, Korey WS: Death by "ecstasy": The serotonin syndrome? Ann Emerg Med 1998; 32:377–380
   PubMed Web of Science ®Google Scholar
• Brown C, Osterloh J: Multiple complications from recreational ingestion of MDMA ("Ecstasy"). J Am Med Assoc 1987; 258:780–781
   PubMed Web of Science ®Google Scholar
• Chadwick IS, Linsley A, Freemont AJ, et al.: Ecstasy, 3,4-methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J Roy Soc Med 1991; 84: 37.
   Google Scholar
• Campkin NTA, Davies UM: Another death from Ecstasy. J Royal Soc Med 1992; 85:61
   PubMed Web of Science ®Google Scholar
• Roberts L, Wright H: Survival following intentional massive overdose of 'Ecstasy.' J Accidental Emerg Med 1993; 11:53–54
   Google Scholar
• Lehmann ED, Thom CH, Croft DN: Delayed severe rhabdomy-alysis after taking ecstasy. Postgrad Med J1995; 71:186–187
   Google Scholar
• Coore JR: A fatal trip with ecstasy: A case of 3,4-methylenedioxy-methamphetamine/3,4-methylenedioxy-ampthetamine toxic-ity. J Royal Soc Med 1996; 89:51P–52P
   Google Scholar
• Green AR, Sanchez V, O'Shea E, et al.: Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylene-dioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA. Psychopharmacol (Berl) 2004; 173: 264–269
   Google Scholar
• Liechti ME, Vollenweider FX: The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (`Ecstasy') in healthy volunteers. J Psychopharmacol 2000; 14:269–274
   PubMed Web of Science ®Google Scholar
• Chance M: Aggregation as a factor influencing the toxicity of sympathomimetic amines in mice. J Pharmacol Exp Ther 1946; 198:214–219
   Google Scholar
• Hohn R, Lasagna L: Effects of aggregation and temperature on amphetamine toxicity in mice. Psychopharmacologia 1960; 1:210–220
   Google Scholar
• Lamb RJ, Griffiths RR: Self-injection of 3,4-methylene-dioxymethamphetamine MMDMA) in the baboon. Psychphar-macol 1987; 91:268–272
   Google Scholar
• Beardsley PM, Balster RL, Harris LS: Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkey. Drug Alcohol Depend 1986; 18:149–157
   PubMedGoogle Scholar
• Glennon RA, Young RY: Further investigations of the discrim-inative stimulus properties of MDA. Pharmacol Biochem Behav 1984; 20:501–505
   Google Scholar
• Kamien JB, Johanson CE, Schuster CR, et al.: The effects of (+)-methylenedixoymethamphetamine and (+)-methylene-dioxyamphetamine in monkeys trained to discriminate (+)- 18:139–147
   Google Scholar
• Fletcher PJ, Robinson SR, Slippoy DL: Pre-exposure to (+/—) 3,4-methylenedioxymethamphetamine (MDMA) facilitates acquisition of intravenous cocaine self-sdministration in rats. Neuropsychopharmacol 2001; 25:195–203
   Google Scholar
• Hubner CB, Bird M, Ressnick S, et al.: The threshold lwering effects of MDMA (ecstasy) on brain-stimulation reward. Psy-chopharmacol 1988; 95:49–51
   Google Scholar
• Sanchez V, Camarero J, Esteban B, et al.: The mechanisms involved in the long-lasting neuroprotective effect of fluoxet-Me against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat blind. Br J Pharmacol 2001; 134: 46–57
   Google Scholar
• Thompson MR, Li KM, Clemens KJ, et al.: Chronic fluoxetine treatment partly attenuates the long-term anxiety and depres-sive symptoms induced by MDMA (`Ecstasy') in rats. Neuro-psychopharmacol 2004; 29:694–704
   Google Scholar
• Pacifici R, Pichini S, Zuccaro P. et al.: Paroxetine inhibits acute effects of MDMA on the immune system in humans. J Pharmacol Exp Then 2004; 309:285–292
   Google Scholar
• Blessing WW, Seaman B, Pedersen NP, et al.: Clozapine reverses hyperthermia and sympathetically mediated cutane-ous vasoconstriction induced by 3,4-methylenedioxymetham-phetamine (ecstasy) in rabbits and rats. J Neurosci 2003; 23: 6385–6391
   Google Scholar
• Fantegrossi WE, Kiessel CL, Leach PT, et al.: Nantenine: An antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacol (Berl) 2004; 173:270-277 amphetamine from saline. Drug Alcohol Depend 1986; saline. Drug Alcohol Depend 1986;
   Google Scholar